FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								

hours per response:

0.5

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* McCamish Mark Anthony					AV	2. Issuer Name and Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC [AVDL]								neck all a	nip of Reporti oplicable) ector	ng Per	10% Ov	/ner	
(Last)	t) (First) (Middle) AVADEL PHARMACEUTICALS PLC					3. Date of Earliest Transaction (Month/Day/Year) 08/01/2023									cer (give title ow)		Other (s below)	pecify	
10 EARLSFORT TERRACE					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) DUBLIN	ureet) UBLIN 2 L2 D02 T380)											Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tabl	e I - Non	-Deriva	ative :	Sec	urities	Ac	quired, D	ispo	osed o	f, or Bo	eneficia	lly Ow	ned				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)					ay/Year) Ex		A. Deemed Execution Date, f any Month/Day/Year)		Transaction Dispose Code (Instr. 5)		Disposed	rities Acquired (A) o ed Of (D) (Instr. 3, 4		d Sec Ben Owi	nount of irities eficially ed Following orted	Forn (D) o	orm: Direct) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	/	Amount	mount (A) or (D)		Trai	saction(s) r. 3 and 4)			Instr. 4)		
		T							uired, Dis , options,					y Own	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price Derivat Securit (Instr. 5	ve derivative Securitie	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Exp	oiration te	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$14.1	08/01/2023			A		33,000		(1)	08/0	01/2033	ADSs ⁽²⁾	33,000	\$0	33,00	0	D		

Explanation of Responses:

- 1. Options shall vest in full on the earlier to occur of (a) August 1, 2024 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.
- 2. The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

/s/ Jerad G. Seurer, as Attorney-in-Fact

08/03/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.